AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05677490
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05677490
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05172518
Drug: Taxane plus Intermittent Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Trial: NCT05172518
Drug: Utidelone plus Intermittent Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Trial: NCT05172518
Drug: Taxane plus Metronomic Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine ( 500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(For the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Trial: NCT05172518
Drug: Utidelone plus Metronomic Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Trial: NCT05894148
Drug: Genakumab injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: 120mg Q4W，group 2: 200mg Q4W
Trial: NCT05894148
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection.
Trial: NCT04929210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as subcutaneous injection.
Trial: NCT05169567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05848713
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient.~Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement.
Trial: NCT06731764
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive Levothyroxine/Placebo~Levothyroxine/Liothyronine with Liothyronine administered twice daily.
Trial: NCT06731764
Drug: Levothyroxine/Liothyronine once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Levothyroxine/Liothyronine with Liothyronine administered once daily;
Trial: NCT04673799
Drug: MV088 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MV088 injection (60mg) by subcutaneous injection once on the first day
Trial: NCT04673799
Drug: Prolia® injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolia® injection (60mg) by subcutaneous injection once on the first day
Trial: NCT05552274
Drug: ECC4703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECC4703 will be administered as 1 mg, 10 mg and 40 mg capsules. ECC4703 will be administered as oral capsules during each dosing day.
Trial: NCT05552274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be administered as oral capsules. Matching Placebo will be given orally during each dosing day.
Trial: NCT06347770
Drug: Probiotic Blend Oral Tablet
RxNorm normalized name: Probiotic Blend Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In our study, forty pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 #106 CFU) by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered four tablets three times a day (2 g/d) for seven days before surgery until the fourth day after surgery.
Trial: NCT04968912
Drug: Standard of Care Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
Trial: NCT04582669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 1 mL sodium chloride 0.9% in up to 3 anatomic areas.
Trial: NCT06358430
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV
Trial: NCT05454332
Drug: Early Caffeine administration
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
Trial: NCT05635318
Drug: FDA approved medications for ADHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)
Trial: NCT04857047
Drug: BR9003 2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003 tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it.
Trial: NCT04857047
Drug: BR9003A 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003A tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it. Another BR9003A tablet will be administered orally with water 150mL around 20:30 after dinner between 18-19:00.
Trial: NCT04906590
Drug: [18F] PI-2620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of the radiopharmaceutical imaging agent PI-2620 in detecting TAU brain burden.
Trial: NCT03338764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep
Trial: NCT06077877
Drug: GSK4524101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK452101 will be administered.
Trial: NCT04082481
Drug: TAK-988 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-988 placebo-matching tablets.
Trial: NCT06151847
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06424288
Drug: vicadrostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicadrostat
Trial: NCT06424288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 690517
Trial: NCT05242484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as subcutaneous injection.
Trial: NCT04489589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg PO/NG q8h
Trial: NCT06033131
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, two tablets three times daily taken orally. Once the participants have been recruited, they will start by taking one tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
Trial: NCT00483795
Drug: sodium citrate, sodium chloride, sodium borate, propylene glycol. citrate, tetronic 1304, AMP 95
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06312176
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablet
Trial: NCT06312176
Drug: Liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05403450
Drug: Decitabine + Cedazuridine
RxNorm normalized name: cedazuridine / decitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration
Trial: NCT05678647
Drug: Iron Sulfate
RxNorm normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 tablets of oral iron sulphate (Duroferon®) 100 mg is given after blood donation
Trial: NCT04914767
Drug: Nigella
RxNorm normalized name: NIGELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days.
Trial: NCT04953910
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
Trial: NCT04914767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days.
Trial: NCT05663866
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered subcutaneously.
Trial: NCT06337162
Drug: INCB099280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg Tablet
Trial: NCT06362447
Drug: Gentamicin Injectable Solution
RxNorm normalized name: gentamicin Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (10 mg/kg) will be administrated once weekly for 3 months
Trial: NCT05514197
Drug: Ascorbic acid 5000mg
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous loading of 5000mg ascorbic acid with normal saline, totally 100ml Completed before surgical incision
Trial: NCT04600336
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06500676
Drug: GFH375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFH375 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
Trial: NCT06324357
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Xeloda®
Trial: NCT06159673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACP-204 matching placebo
Trial: NCT04657081
Drug: Decitabine and Cedazuridine (ASTX727)
RxNorm normalized name: cedazuridine / decitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration: oral in the form of a tablet
Trial: NCT05968326
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRINOX (oxaliplatin, leucovorin, irinotecan, 5-FU) will be administered IV at specified timepoints.
Trial: NCT05174169
Drug: CAPOX 3 month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles
Trial: NCT05174169
Drug: CAPOX 6 month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles
Trial: NCT05060731
Drug: Oral iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca. 200-300 mg of ferrous sulfate will be administered orally every day for 3 months.
Trial: NCT05060731
Drug: Intravenous iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of intravenous 1000 mg ferric carboxymaltose will be administered on the day of randomization.
Trial: NCT04739800
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05422222
Drug: VX-121/TEZ/D-IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination for oral administration.
Trial: NCT06658574
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1: Once cleared for oral intake - acetaminophen tablets 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days\&#39; dispensed as unit-dose tablets Arm 2: Once cleared for oral intake - acetaminophen liquid (160 mg/5 mL) 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days; 650 mg = 20.3 mL, dispensed as a unit-dose cup
Trial: NCT06662786
Drug: Leucovorin calcium/Levoleucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
Trial: NCT06600412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Please refer to arm/group description for further information.
Trial: NCT05694533
Drug: INDV-2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally twice a day
Trial: NCT06397911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study treatment will be administered as 5 SC doses in total 12 weeks
Trial: NCT05905783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection
Trial: NCT04810091
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06243354
Drug: Test product: HYP-2090PTSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: Capsule. Strength: 2.5 mg, 5 mg. Method of administration: Oral; Dose escalation: a fixed dose QD is planned, and all other dose levels and administration methods are temporary with the exception of the initial dose. Dose expansion: the dose and method of administration are conducted as discussed by the sponsor and investigators.~Medication cycle: Take orally under fasting condition every morning, with 21 days as a cycle (tentative), and continue taking until disease progression, or intolerable toxicity, or withdrawal of informed consent, or treatment with another antitumor drug, or the death of the subject, or loss to follow-up (whichever occurs earliest).
Trial: NCT06252649
Drug: FOLFIRI Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of irinotecan, leucovorin, and 5-fluorouracil given intravenously Q2W.
Trial: NCT05838547
Drug: 64Cu-25%-CANF-Comb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients treated with OMT alone that are not treated with CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit and at 12-18 months, or earlier if they develop symptoms. While 12-18 months is the preferred window for repeat imaging, if imaging during this time frame is not achievable, the patient may return anytime throughout the remainder of the study.
Trial: NCT05838547
Drug: 64Cu-25%-CANF-Comb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients treated with OMT and CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit.
Trial: NCT05255302
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
Trial: NCT05358548
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
Trial: NCT06685757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 0.9% saline solution by intravenous infusion.
Trial: NCT06700538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calculated volume to match active treatment by SC injection
Trial: NCT06723106
Drug: RAY121
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT06707103
Drug: TR987 0.1% gel + Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)
Trial: NCT05981963
Drug: [14C]-BMS-986196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05790213
Drug: Androgen Deprivation Therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT therapy will consist of any generic luteinizing hormone-releasing hormone agonist which will provide either 6-months of treatment or two injections every 3-months. (e.g., one injection with a treatment period of 6 months or two injections, one at drug start and one 3-months later).
Trial: NCT06309966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo taken once daily
Trial: NCT06761976
Drug: BAY2927088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY2927088 is self-administered by the patient BID (twice a day) as tablets for oral administration
Trial: NCT05286814
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
Trial: NCT06721156
Drug: MK-1167
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1167 oral capsule
Trial: NCT06721156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule